tbuckley/cabot-search huggingface dataset:
Toxicity of bevacizumab (BV) in metastatic colorectal carcinoma (MCRC): Analysis in 173 consecutive patients
Authors: J. Ferreiro, I. Diaz de Corcuera, J. M. Mañé, A. Sancho, A. Muñoz, N. Fuente, G. López de Argumedo, A. Moreno, I. Rubio, A. Ruiz de Lobera
Journal: Journal of Clinical Oncology (2008)

15069 Background: BV is an active antiangiogenic agent in MCRC with a specific toxicity profile. We analyzed the toxicity of all patients with MCRC treated with BV in our Department. Methods: Between September/2004 and May/2007 173 patients, 116 men (67.1%), received BV, mean age: 63.8 (29–84). Previous medical conditions: hypertension 48 (27.7%), cerebrovascular disease 10 (5.8%), ischemic cardiomiopathy 8 (4.6%), deep venous thrombosis/pulmonary thromboembolism 7 (4%), nonsmokers 87 (53%). Aspirin consumers 9 (5.2%), other antiaggregants 9 (5%) and anticoagulated 14 (8%), (2% LMWH, 6% dicoumarin). BV was administered associated to FOLFIRI (62.5%), IFL (26%), XELOX (6.4%), 5FU+FA (2.3%), FOLFOX (2.3%) and CPT-11 (0.5%). First line therapy 49.7% and 9 patients received BV in more than a line. Median number of cycles: 7 (1–33). Results: Toxicities 1–2/3–4 (%): Hypertension 21.5/0; Hemorrhage 66.8/1.2: Fistulae 0/2.9; Perforation 0/1.8; Venous thromboembolic events 0/2.9; Proteinuria 13.4/2.9 and cerebrovascular ischemic events 0.6/1.2; Anastomotic leakage 0/0.5. The risk of haemorrhage increases significantly in nonsmokers (p=0.006) and in hypertensive patients (p=0.046). Intestinal perforation increases significantly in aspirin consumers (p=0.006), aspirin or other antiaggregants (p=0.001) and aspirin or other antiaggregants or anticoagulants (p=0.004). Aspirin consumers have a higher frequency of perforation-fistulae (p=0.035). Patients with a medical history of vascular disease tend to have a higher frequecy of intestinal perforations (p=0.051). Patients with unresected primary tumour also tend to a higher frequency of perforation-fistulae (p=0.071). Conclusions: BV toxicity in patients outside clinical trials is similar to the described in the studies. Aspirin consumption favours perforation. No significant financial relationships to disclose.
Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.
Authors: Andrey Loboda, Valeria Fantin, Sophia Randolph, Justin L. Ricker, James S. Hardwick, Victoria M. Richon, Stanley R. Frankel
Journal: Blood (2006)
Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms
Authors: Lakshmikanth Katragadda, Hagop M. Kantarjian, Guillermo Garcia-Manero, Tapan M. Kadia, Alessandra Ferrajoli, Elias J. Jabbour, Alfonso Quintas-Cardama, Marina Konopleva, Manoj Maniar, Francois Wilhelm, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2012)
Our resection outcome in lung cancer: Evaluation of 45 consequential patients
Authors: R. Demirhan, A. Mayadagli MD, C. Parlak MD, M. Kocak, A. Ozkan, M. Gumus
Journal: Journal of Clinical Oncology (2008)

18508 Background: Surgical treatment is an important therapeutic option in lung cancer, providing a long-term survival and curability. We analyzed our resection series retrospectively. Methods: Patients who had been diagnosed with lung cancer in our hospital from 2004 to 2007 were evaluated in the study. Results: Three hundred ninety-six patients had been diagnosed as lung cancer in the pulmonology and thoracic surgery clinics of our hospital from 2004 to 2007. However, surgical treatment could be performed to only 45 of these patients (11.3%). Two patients were female and 43 were male. Mean age was 61 (38–74) in the study. Preoperative diagnosis was established with fiberoptic bronchoscopy in 28 patients (62%), with rigid bronchoscopy in 4 patients (8.8%), with transthoracic needle aspiration biopsy in 7 patients (15.5%) and open lung biopsy in 6 patients (13.6%). Preoperative histopathologic evaluation diagnosed 38 patients as non-small-cell lung cancer and one patient as small-cell lung cancer, whereas diagnosis of non-small-cell lung cancer was made by open lung biopsy. For staging purposes, mediastinoscopy was performed to 41 patients (91%) and additional anterior mediastinotomy was carried out in 5 patients (11%). Mediastinal involvement (N2 +) was noted in two patients with mediastinoscopy. Lobectomy was the most frequent resection procedure performed (in 62%). Epidermoid carcinoma was reported to be the most frequent postoperative histopathologic diagnosis. In our series, postoperative complication was noticed in 5 patients (11.1%) while postoperative mortality was observed in 3 patients (6.6%). Postoperative follow-up period was 18 months in our series. Patients with stage I and II lung cancer, who had been operated, were observed to experience no problem. Conclusions: In conclusion, surgical resection is the most effective treatment option recommended for the treatment in non- small-cell lung cancer. No significant financial relationships to disclose.
Canadian medical oncologists' practice and perception on accessing new drugs for patients with metastatic colorectal cancer: A national survey
Authors: K. K. Chan, S. R. Berry, S. Straus, J. Chang, L. L. Siu
Journal: Journal of Clinical Oncology (2008)

6600 Background: Canada is known for its publically funded health care system. Traditionally, IV cancer drugs are approved federally but funded by provincial health plans (PHP) and administered in public institutions without private payment (PP). PP is now permitted in some public institutions and private clinics. Canadian medical oncologists (MO) who treat metastatic colorectal cancer (CRC) face challenges in providing expensive drugs (Oxaliplatin (O), Bevacizumab (B) and Cetuximab (C)). O did not receive regulatory approval until June 2007. At the time of this survey, B was funded in 2 provinces. C is not marketed in Canada or funded by PHP. We conducted a national survey of MO who treated CRC to examine how challenges in accessing O, B, and C impacted their practice. Methods: The survey was developed using modified Delphi method focusing on impact of funding on clinical practice and opinions on the funding processes. Electronic and mail surveys were distributed to Canadian CRC MO. Results: 35% (57/164) of CRC MO responded. 41%, 61% & 41% provided O, B & C through clinical trials. Off trial, 70% and 65% did not routinely use what they considered as ideal 1st line regimen (1stIR) and ideal 3rd line regimen (3rdIR) respectively. 86% considered B as part of 1st IR but only 18% routinely used B. 20% provided B by PHP, 27% provided B by PP, 29% sent pts to private infusion clinics and 23% sent pts to outside their cities/provinces/to USA to receive B. 30% reported O as part of their 1stIR but only 9% routinely used O in 1st line. 37% reported PP partly paying for O. 88% considered C as part of 3rdIR but only 30% routinely used C. 20% provided C by PP, while 36% sent pts to USA to receive C paid by PHP. 77% and 52% agreed that PP should be allowed in their centres and private infusion clinics respectively. 85% supported the creation of a national drug formulary to approve and fund drugs. Only 10% and 17% were satisfied with the current drug approval process and provincial funding process respectively. Conclusions: Most Canadian CRC MO did not routinely deliver their ideal regimens in their own centres off trial because parts of those regimens were not funded by PHP, resulting in some pts receiving treatments far away from home. Majority favored PP for drugs not covered by PHP. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Roche, sanofi-aventis Bristol-Myers Squibb, Roche
TCT-178 Spontaneous coronary artery dissection (SCAD): Predictors and Long-term outcome
Authors: Santiago J. Camacho Freire, Livia L. Gheorghe, Jessica Roa-Garrido, Antonio Gomez Menchero, Rosa M. Cardenal, Javier Leon Jimenez, Prudencia Gomez Fernandez, Francisco J. Landero Garcia, Jose F. Diaz Fernandez
Journal: Journal of the American College of Cardiology (2015)
Emergence of New lesions upon Treatment failure is an Independent, Negative Prognostic Factor for Patients with Primary Refractory DLBCL
Authors: Nobuhiko Yamauchi, Yusuke Koba, Yotaro Ochi, Yasuhiro Kazuma, Yosuke Nagahata, Yuichiro Ono, Nobuhiro Hiramoto, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Yukihiro Imai, Takayuki Ishikawa
Journal: Blood (2014)
TCT-168 Prosthesis-Patient Mismatch after Aortic Valve-In-Valve Implantation: Insights from the Valve-in-Valve International Data (VIVID) Registry
Authors: Sabine Bleiziffer, John Webb, Ran Kornowski, David M. Holzhey, Matheus S. Santos, Isaac George, Jan-Malte Sinning, Massimo Napodano, Luis Nombela-Franco, Mayra Guerrero, Henrik Nissen, Tanja Rudolph, Stephen Brecker, Ashish Shah, Petur Petursson, Alfredo Giuseppe Cerillo, Sujay Chandran, Neil Moat, Diego F. Gaia, Seung-Jung Park, Nikolaos Bonaros, Raffi Bekeredjian, Ruediger Lange, Danny Dvir
Journal: Journal of the American College of Cardiology (2015)
Three New Mutations of Glucose-6-Phosphate Isomerase Associated with Chronic Hemolytic Anemia.
Authors: Cristina Vercellati, Elisa Fermo, Anna Marcello, Mariagabriella Mariani, Paola Bianchi, Wilma Barcellini, Saverio Ladogana, Alessandro De Fanti, Alberto Zanella
Journal: Blood (2004)
TCT-587 Bioabsorbable polymer-coated thin strut everolimus-eluting synergy stent for coronary revascularization in daily clinical practice: One-year results of the SWEET registry
Authors: Serban Puricel, Lorenz Raber, Dik Heg, Mathieu Stadelmann, Kyohei Yamaji, Thomas Zanchin, Philip Urban, Estelle Boute, Peter Wenaweser, Mario Togni, Edoardo De Benedetti, Stephan Windecker, Stéphane Cook
Journal: Journal of the American College of Cardiology (2015)
Relationship Between Metabolic Tumor Volume and Rituximab Pharmacokinetic Parameters in Non-Hodgkin’s Lymphoma
Authors: Helene Monjanel, David Ternant, Yann Venel, Caroline Prunier-Aesch, Jean-François Tournamille, Flavie Arbion, Philippe Colombat, Gilles Paintaud, Emmanuel Gyan
Journal: Blood (2014)
O093 : The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis : Results of a randomized controlled clinical trial
Authors: S. Piano, F. Salinas, F. Morando, M. Cavallin, A. Romano, S. Rosi, M. Stanco, S. Fasolato, A. Sticca, M. Senzolo, P. Burra, G. Zanus, U. Cillo, A. Gatta, P. Angeli
Journal: Journal of Hepatology (2015)
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches
Authors: Rita Diehl, Fabienne Ferrara, Claudia Müller, Antje Y Dreyer, Damian D McLeod, Stephan Fricke, Johannes Boltze
Journal: Cellular and Molecular Immunology (2016)

Almost every experimental treatment strategy using non-autologous cell, tissue or organ transplantation is tested in small and large animal models before clinical translation. Because these strategies require immunosuppression in most cases, immunosuppressive protocols are a key element in transplantation experiments. However, standard immunosuppressive protocols are often applied without detailed knowledge regarding their efficacy within the particular experimental setting and in the chosen model species. Optimization of such protocols is pertinent to the translation of experimental results to human patients and thus warrants further investigation. This review summarizes current knowledge regarding immunosuppressive drug classes as well as their dosages and application regimens with consideration of species-specific drug metabolization and side effects. It also summarizes contemporary knowledge of novel immunomodulatory strategies, such as the use of mesenchymal stem cells or antibodies. Thus, this review is intended to serve as a state-of-the-art compendium for researchers to refine applied experimental immunosuppression and immunomodulation strategies to enhance the predictive value of preclinical transplantation studies.
Combination Therapy of Anti-Cancer Drug with FNIII14 Peptide of Fibronectin Effectively Overcome Cell Adhesion Mediated-Drug Resistance of Acute Myelogenous Leukemia.
Authors: Takuya Matsunaga, Fumio Fukai, Maki Tanaka, Masayoshi Kobune, Hiroki Chiba, Yoshiro Niitsu
Journal: Blood (2006)
Factor V Deficiency in a Patient with Polycythemia Vera and Huntington’s Chorea
Authors: Fotios I Girtovitis, Michael D. Diamantidis, Georgia Kaiafa, Nikolaos Constantinou, Despina Lazaridou, Zoi Saouli, George Ntaios, Zisis Kontoninas, Charalambos Andreadis, Athanasios Papadopoulos
Journal: Blood (2008)
Phenotypic Analysis of Plasma Cells in Monoclonal Gammopathy and Multiple Myeloma Subjects.
Authors: Lucie Kovarova, Ivana Buresova, Ludek Pour, Renata Suska, Zdenek Adam, Marta Krejci, Jiri Vorlicek, Miroslav Penka, Roman Hajek
Journal: Blood (2007)
Superficial lipomas associated with malignancies (S.L.A.M. Syndrome)- Report of a new syndrome
Authors: L. S. Maddali
Journal: Journal of Clinical Oncology (2004)

9691 Background: Superficial lipomas are common,benign tumours that rarely undergo malignant change.A few syndromes of lipomatoses are associated with malignancies(Cowden syndrome,Bannayan-Riley-Ruvulcaba syndrome).We report a new syndrome distinct from the established diseases in literature.Methods:Clinical examination,Fine Needle Aspiration Cytology/Excision biopsy in a few cases enabled us to identify 93 cases with superficial lipomas in association with 95 malignancies.These cases were seen among 2683 patients we encountered between December 1st 1998 to December 1st 2003.Results:41 Cases of Hematologic malignancies( Non Hodgkins lymphomas-16;Multiple Myeloma 8;Chronic Myeloid Leukemia 7;Acute Myeloid Leukemia 4;Myelodysplastic syndrome 2;Hodgkins Disease 2;Chronic Lymphocytic Leukemia 2)were identified.52 cases had 54 solid tumours in variousorgans:Adenocarcinomas46(Breast18;Lung14;Ovary5;prostate3; Colon2;Liver2;Kidney1;Stomach1;)Transitional Carcinoma of bladder2;Seminoma of testis 1;PagetsDisease of scrotal skin 1;Sarcomas 4(Triton tumour1,Liposarcomas2,round cell sarcoma1) Conclusions: S.L.A.M. syndrome is distinct from other lipomatoses associated malignancies:Adult age of occurance,absence of macrocephaly,mental retardation,or tumours of thyroid and central nervous system.In addition hematologic neoplasms are being reported in S.L.A.M.symdrome.Notable absences include tumours of brain,bones,squamous cell carcinomas of upper aerodigestive tract,round cell neoplasms of childhood,nonseminomatous germ cell tumours. No significant financial relationships to disclose.
GW27-e1121 Association between Serum Lipoprotein-Associated Phospholipase A2 Level and Carotid Artery Arteriosclerosis in Patients with Impaired Glucose Tolerance
Authors: Wang Yina, Qiongli Yin, Shangyan Liang, Benrong Zheng, Qingling Li, Mei Li, Xiaoming Ye
Journal: Journal of the American College of Cardiology (2016)
TCT-676 Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Yulanka Castro Dominguez, Atish P. Mathur, Daniel Angeli, Thomas Cocke, Pranaychandra Vaidya, Elie M. Elmann, Gabriele Di Luozzo, Arthur Ng, Elly Delaportas, Nierenberg Hillary, Joseph Parrillo
Journal: Journal of the American College of Cardiology (2015)
Survival following primary androgen deprivation therapy among men with localized prostate cancer
Authors: S. Yao, D. F. Moore, W. J. Shih, Y. Lin, R. S. DiPaola, P. C. Albertsen, G. L. Lu-Yao
Journal: Journal of Clinical Oncology (2008)

5014 Background: Despite a lack of data, increasing numbers of patients have turned to primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation or active surveillance for the management of localized prostate cancer. We studied the impact of PADT on survival and use of secondary therapy in elderly men with localized prostate cancer. Methods: Medicare claims linked to Surveillance, Epidemiology and End Results (SEER) data were used to assemble a cohort of 19,271 men with T1-T2 prostate cancer without local therapy within 6 months of cancer diagnosis. Instrumental variable analysis was used to overcome potential overt and hidden biases associated with unmeasured confounding variables. Results: Even though 41% of the population received PADT (median age 77), PADT use was not associated with improved median overall survival (114 vs. 113 months, hazard ratio [HR] 1.00; 95% CI 0.95–1.05) or cumulative risk of receiving secondary cancer therapy (31% at 10 years, HR 0.95; 95% CI 0.88 - 1.04) compared to active surveillance. However, in a pre- specified subset analysis, PADT use in men with poorly-differentiated cancer was associated with improved median overall survival (88 vs. 81 months, HR 0.90; 95% CI 0.82–1.00) and lower cumulative risk of receiving secondary therapy (29% vs. 35% at 10 years, HR 0.79, 95% CI 0.66 - 0.94). Findings: PADT does not improve survival or reduce the use of secondary cancer therapy among the majority of elderly men with localized prostate cancer, although there is some suggestion of potential benefit among men with poorly-differentiated cancer. Weighing the potential risks and benefits of PADT is critical for making informed treatment decisions. No significant financial relationships to disclose.
JAK inhibition in STING-associated interferonopathy
Authors: Mathieu P Rodero, Marie-Louise Frémond, Gillian I Rice, Bénédicte Neven, Yanick J Crow
Journal: Annals of the Rheumatic Diseases (2016)

We read with interest the paper by Konig et al 1 describing a novel pathogenic mutation in TMEM173 . This report is important in highlighting the stable segregation of a skin-restricted phenotype across four generations, thus expanding the clinical spectrum associated with gain-of-function mutations in stimulator of interferon genes (STING). These authors also report the use of the Janus kinase (JAK)1/3 inhibitor tofacitinib in two of their patients. Unfortunately, since the treatment period was limited to a total of 17 days, it was not possible to draw any conclusions as to therapeutic efficacy. However, we have recently described the use of an alternative JAK(1/2) inhibitor, ruxolitinib, in three STING-mutated patients treated for a period of up to 18 months.2 Importantly, in this study, we observed a marked improvement in all three major …
Those were the days
Authors: Theodore Dalrymple
Journal: BMJ (2008)

T S Eliot was not the most accessible of writers, to put it mildly, but he wanted to show that he could write plays that would please the general public. Reading the products of his attempted demonstration rather puts me in mind of the duke who, reproached for never having ridden on a bus and for therefore being out of touch with the common people, promptly jumped on a bus to prove the accusation false and said to the driver, “Grosvenor Square, and quick!”

Oddly enough, however, Eliot’s plays were a success (the script of The Cocktail Party even became a bestseller in America), which suggests that …
Prospective trial with preoperative gefitinib to correlate lung cancer response with <i>EGFR</i> exon 19 and 21 mutations and to select patients for adjuvant therapy
Authors: M. G. Kris, W. Pao, M. F. Zakowski, M. Ladanyi, R. T. Heelan, L. Schwartz, B. Zhao, E. Venkatraman, V. Rusch, N. A. Rizvi
Journal: Journal of Clinical Oncology (2006)

7021 Background: Induction therapy provides a unique opportunity for the objective assessment of therapies in patients with NSCLC to facilitate care and advance research. We designed this 40 patient prospective trial to measure gefitinib’s ability to induce regressions preoperatively in individuals with NSCLC and to simultaneously correlate response with mutations in EGFR exons 19 and 21. Patients with ‘in-vivo‘ gefitinib sensitivity and/or mutations receive gefitinib postoperatively as well. To facilitate our goals, we enriched the population studied to select individuals with tumors more likely to harbor mutations in EGFR. Methods: At diagnosis, patients with stage I or II NSCLC had baseline chest CT imaging and a core-needle biopsy to detect EGFR mutations. All participants smoked cigarettes ≤ 10 pack years and/or had tumors with bronchioloalveolar features. All received gefitinib 250 mg daily. After 21 days, CT imaging was repeated and resection followed. Surgical specimens were agained assayed for EGFR mutations. Patients with mutation and/or a ≥ 25% regression (WHO) were given gefitinib 250 mg for 2 years. Results: 20 patients enrolled to date. EGFR mutations were detected in both pre and post gefitinib specimens in 4/19 tested (21%). Five of 19 (26%) had a ≥ 25% bidimensional tumor reduction after 3 weeks. Regressions ≥ 25% were seen in 2/4 (50%) with exon 19 and 21 EGFR mutations and 3/15 (20%) with WT EGFR. The other 2 patients with mutations had 11% and 23% tumor regressions. The 6 patients who had either a ≥ 25% lesion reduction and/or mutation received gefitinib postoperatively. No perioperative complications related to gefitinib occurred. All patients are relapse free. Conclusions: In this ongoing trial, 1) Our ‘enrichment strategy‘ resulted in the detection of twice the expected number of EGFR mutations in USA patients with NSCLC. 2) Gefitinib sensitivity can be assessed by CT in 3 weeks. 3) Results of mutation detection were identical in pre- and post-treatment specimens. 4) The rate of response is numerically higher in patients with EGFR mutations in exons 19 and 21. 5) We are using the surgical specimens to elucidate determinants of gefitinib sensitivity in the absence of EGFR mutation. Support: CA05826, CA113653. [Table: see text]
Genome-Wide Biases in the Rate and Molecular Spectrum of Spontaneous Mutations in<i>Vibrio cholerae</i>and<i>Vibrio fischeri</i>
Authors: Marcus M. Dillon, Way Sung, Robert Sebra, Michael Lynch, Vaughn S. Cooper
Journal: Molecular Biology and Evolution (2016)

The vast diversity in nucleotide composition and architecture among bacterial genomes may be partly explained by inherent biases in the rates and spectra of spontaneous mutations. Bacterial genomes with multiple chromosomes are relatively unusual but some are relevant to human health, none more so than the causative agent of cholera, Vibrio cholerae Here, we present the genome-wide mutation spectra in wild-type and mismatch repair (MMR) defective backgrounds of two Vibrio species, the low-%GC squid symbiont V. fischeri and the pathogen V. cholerae, collected under conditions that greatly minimize the efficiency of natural selection. In apparent contrast to their high diversity in nature, both wild-type V. fischeri and V. cholerae have among the lowest rates for base-substitution mutations (bpsms) and insertion-deletion mutations (indels) that have been measured, below 10-3/genome/generation. Vibrio fischeri and V. cholerae have distinct mutation spectra, but both are AT-biased and produce a surprising number of multi-nucleotide indels. Furthermore, the loss of a functional MMR system caused the mutation spectra of these species to converge, implying that the MMR system itself contributes to species-specific mutation patterns. Bpsm and indel rates varied among genome regions, but do not explain the more rapid evolutionary rates of genes on chromosome 2, which likely result from weaker purifying selection. More generally, the very low mutation rates of Vibrio species correlate inversely with their immense population sizes and suggest that selection may not only have maximized replication fidelity but also optimized other polygenic traits relative to the constraints of genetic drift.